BioAge Stock Rallies 29% Following Upsized $198M IPO
EXCLUSIVE: Vivani Medical Advances Its Obesity Treatment Implant With New Clinical Trial in Australia
Evotec, Novo Nordisk Forms Technology Development Partnership for Stem Cell-based Therapies
Eli Lilly Stock Soars In 2024 On Weight Loss Drug Success, Now The Company Wants Medical Records Of Copycat Treatments
Lose Weight With Novo Nordisk Drugs, Gain Money With Stock
Popular Ozempic May Have New Use As Semaglutide Drugs Linked To Reduced Overdose Risk In Diabetic Opioid Users
FDA Approves Osimertinib For Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer After Chemoradiation Therapy; Recommended Dose Is 80mg Daily Until Disease Progression Or Unacceptable Toxicity
Next Frontier in Anti-obesity Landscape: Oral GLP-1s With Potential OTC Switch
Can Novo Nordisk's Weight Loss Drug Ozempic Help Stem The Devastating Addiction Crisis? New Research Says Yes
Eli Lilly Unusual Options Activity
Viking Therapeutics Analyst Ratings
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs
BioAge, Obesity Drug Developer, Upsizes Proposed IPO
Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability
Novo Nordisk, Lilly Weight Loss Drugs Poised for Price Reductions: Cantor's Louise Chen
Lilly Ebglyss Demonstrates Durable Disease Control in Atopic Dermatitis
EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen'
US stocks closed: S&P, Dow hit new highs again. Chinese concept stocks staged a 'Golden Dragon Soaring'.
1. The three major indices collectively rose, with the S&P 500 index and the Dow hitting new highs; 2. Chinese concept stocks generally soared, with the Nasdaq Golden Dragon Index in China rising by 9.13%; 3. Nvidia rose by about 4%, temporarily halting the selloff by Huang Renxun; 4. The US Department of Justice sued Visa, accusing it of illegal monopolization.
U.S. Senate questions high pricing of 'miracle weight-loss drug' novo-nordisk a/s responds: lowering the price is useless.
①Novo Nordisk's CEO was questioned by the United States Senate, with senators believing that Novo Nordisk's pricing in the USA is too high; ②At the hearing, Novo Nordisk's CEO still refused to commit to lowering the prices of Wegovy and Ozempic; ③After the hearing, Novo Nordisk issued a statement saying that even if the company lowers prices, American patients would not be able to enjoy the corresponding price reductions.
$1000 Invested In Eli Lilly 20 Years Ago Would Be Worth This Much Today